Find a Doctor
30 years in practice
More than 200 published peer reviewed papers
Co-founder, Northeast ALS Clinical Trials Consortium (NEALS)
of Neurology, University of Arizona in Phoenix
of Clinical Research, Barrow and St. Joseph’s Hospital and Medical Center
Creighton University School of Medicine in Phoenix
Jeremy Shefner, MD, PhD, is a neurologist in the Gregory W. Fulton ALS & Neuromuscular Disease Center and professor in the Department of Neurology at Barrow Neurological Institute. He is board certified in neurology by the American Board of Psychiatry and Neurology and he specializes in ALS and neuromuscular disorders.
Dr. Shefner’s research focuses on biomarker development and the clinical therapeutics of amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy. He co-founded the Northeast ALS Clinical Trials Consortium (NEALS), the largest and most active consortium in the world dedicated to ALS. He continues to direct the NEALS outcomes and clinical monitoring cores and is currently the principal investigator for two multicenter clinical trials, as well as a biomarker study evaluating the effectiveness of electrical impedance myography in measuring ALS disease progression.
Dr. Shefner has published approximately 200 papers in peer-reviewed journals and has served on multiple grant review panels. He has also participated in committees organized by the Institute of Medicine to investigate the relationship between military service and ALS, as well as the health effects of Agent Orange on Vietnam War veterans. In 2014, Dr. Shefner received the Sheila Essey Award for ALS Research, presented annually by the American Academy of Neurology and the ALS Association and, in 2023, he received the Forbes Norris Award from the International Alliance of ALS/MND Associations for his exceptional contributions to the management, care, and research of ALS and motor neurone disease.
Dr. Shefner received his PhD in sensory physiology from the University of Illinois in Urbana-Champaign, and his MD from Northwestern University Medical School in Chicago. He completed his residency training at the Harvard Longwood Neurology Training Program in Boston and completed a fellowship in neuromuscular disease at the Brigham and Women’s Hospital in Boston.
For more information on Dr. Shefner, please call (602) 406-6262.
- Aetna
- AHCCS (Referral Required)
- Blue Cross Blue Shield
- Blue Cross Blue Shield Third Party
- Cigna
- Commercial Networks
- Government Plans
- Humana
- Market Place Plans (Referral Required)
- Medicare Advantage Plans (Referral Required)
- United Healthcare
- Fellowship, Brigham and Women’s Hospital and Harvard Medical School, Clinical Neurophysiology, 1988-1990
- NINCDS Postdoctoral Research Fellowship, University of Illinois at Chicago, Sensory Physiology, 1977-1979
- Residency, Harvard-Longwood Neurological Training Program, Neurology, 1984-1988
- Internship, Beth Israel Hospital, Medicine, 1983-1984
- MD, Northwestern University (with distinction), 1983
- PhD, University of Illinois, Psychology, 1976
- MA, University of Illinois, Psychology, 1974
- BS, University of Illinois, Mathematics, 1972
- Founder and Co-Chair, Northeast ALS Clinical Trials Consortium (NEALS)
- American Academy of Neurology
- American Association of Electrodiagnostic Medicine
- American Neurological Association
- Forbes Norris Award, International Alliance of ALS/MND Associations, 2023
- Best Doctors in America, Best Doctors, 2011-2020
- America’s Top Doctors, Castle Connolly, 2010-2020
- Sheila Essey Award for ALS Research, ALS Association and American Academy of Neurology, 2014
- Alpha Omega Alpha, 1982
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Date: 07/2024
Authors: Michael Benatar, Thomas Hansen, Dror Rom, Marie A Geist, Thomas Blaettler, William Camu, Magdalena Kuzma-Kozakiewicz, Leonard H van den Berg, Raul Juntas Morales, Adriano Chio, Peter M Andersen, Pierre-Francois Pradat, Dale Lange, Philip Van Damme, Gabriele Mora, Mariusz Grudniak, Matthew Elliott, Susanne Petri, Nicholas Olney, Shafeeq Ladha, Shafeeq S. Ladha, Namita A Goyal, Thomas Meyer, Michael G Hanna, Colin Quinn, Angela Genge, Lorne Zinman, Duaa Jabari, Christen Shoesmith, Albert C Ludolph, Christoph Neuwirth, Sharon Nations, Jeremy M Shefner, Martin R Turner, Joanne Wuu, Richard Bennett, Hoang Dang, Claus Sundgreen
Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice
Date: 12/2023
Authors: Michael Benatar, Lyle W. Ostrow, Joseph W. Lewcock, Frank Bennett, Jeremy Shefner, Robert Bowser, Paul Larkin, Lucie Bruijn, Joanne Wuu
Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers: A Review
Date: 12/2022
Authors: Jeremy M. Shefner, Richard Bedlack, Jinsy A. Andrews, James D. Berry, Robert Bowser, Robert Brown, Jonathan D. Glass, Nicholas J. Maragakis, Timothy M. Miller, Jeffrey D. Rothstein, Merit E. Cudkowicz
Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development.
Date: 02/2022
Authors: Sabrina Paganoni, James D Berry, Melanie Quintana, Eric Macklin, Benjamin R Saville, Michelle A Detry, Marianne Chase, Alexander V Sherman, Hong Yu, Kristin Drake, Jinsy Andrews, Jeremy Shefner, Lori B Chibnik, Matteo Vestrucci, Merit E Cudkowicz, Shafeeq S. Ladha
Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design
Date: 09/2021
Authors: James Berry, Benjamin Brooks, Angela Genge, Terry Heiman-Patterson, Stanley Appel, Michael Benatar, Robert Bowser, R. Bowser, Merit Cudkowicz, Clifton Gooch, Jeremy Shefner, Jurjen Westra, Wendy Agnese, Charlotte Merrill, Sally Nelson, Stephen Apple
- English
- (602) 406-6262
- Fax: (602) 406-6261
30 years in practice
More than 200 published peer reviewed papers
Co-founder, Northeast ALS Clinical Trials Consortium (NEALS)
of Neurology, University of Arizona in Phoenix
of Clinical Research, Barrow and St. Joseph’s Hospital and Medical Center
Creighton University School of Medicine in Phoenix
Jeremy Shefner, MD, PhD, is a neurologist in the Gregory W. Fulton ALS & Neuromuscular Disease Center and professor in the Department of Neurology at Barrow Neurological Institute. He is board certified in neurology by the American Board of Psychiatry and Neurology and he specializes in ALS and neuromuscular disorders.
Dr. Shefner’s research focuses on biomarker development and the clinical therapeutics of amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy. He co-founded the Northeast ALS Clinical Trials Consortium (NEALS), the largest and most active consortium in the world dedicated to ALS. He continues to direct the NEALS outcomes and clinical monitoring cores and is currently the principal investigator for two multicenter clinical trials, as well as a biomarker study evaluating the effectiveness of electrical impedance myography in measuring ALS disease progression.
Dr. Shefner has published approximately 200 papers in peer-reviewed journals and has served on multiple grant review panels. He has also participated in committees organized by the Institute of Medicine to investigate the relationship between military service and ALS, as well as the health effects of Agent Orange on Vietnam War veterans. In 2014, Dr. Shefner received the Sheila Essey Award for ALS Research, presented annually by the American Academy of Neurology and the ALS Association and, in 2023, he received the Forbes Norris Award from the International Alliance of ALS/MND Associations for his exceptional contributions to the management, care, and research of ALS and motor neurone disease.
Dr. Shefner received his PhD in sensory physiology from the University of Illinois in Urbana-Champaign, and his MD from Northwestern University Medical School in Chicago. He completed his residency training at the Harvard Longwood Neurology Training Program in Boston and completed a fellowship in neuromuscular disease at the Brigham and Women’s Hospital in Boston.
For more information on Dr. Shefner, please call (602) 406-6262.
- (602) 406-6262
- Fax: (602) 406-6261
- Aetna
- AHCCS (Referral Required)
- Blue Cross Blue Shield
- Blue Cross Blue Shield Third Party
- Cigna
- Commercial Networks
- Government Plans
- Humana
- Market Place Plans (Referral Required)
- Medicare Advantage Plans (Referral Required)
- United Healthcare
- Fellowship, Brigham and Women’s Hospital and Harvard Medical School, Clinical Neurophysiology, 1988-1990
- NINCDS Postdoctoral Research Fellowship, University of Illinois at Chicago, Sensory Physiology, 1977-1979
- Residency, Harvard-Longwood Neurological Training Program, Neurology, 1984-1988
- Internship, Beth Israel Hospital, Medicine, 1983-1984
- MD, Northwestern University (with distinction), 1983
- PhD, University of Illinois, Psychology, 1976
- MA, University of Illinois, Psychology, 1974
- BS, University of Illinois, Mathematics, 1972
- Founder and Co-Chair, Northeast ALS Clinical Trials Consortium (NEALS)
- American Academy of Neurology
- American Association of Electrodiagnostic Medicine
- American Neurological Association
- Forbes Norris Award, International Alliance of ALS/MND Associations, 2023
- Best Doctors in America, Best Doctors, 2011-2020
- America’s Top Doctors, Castle Connolly, 2010-2020
- Sheila Essey Award for ALS Research, ALS Association and American Academy of Neurology, 2014
- Alpha Omega Alpha, 1982
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Date: 07/2024
Authors: Michael Benatar, Thomas Hansen, Dror Rom, Marie A Geist, Thomas Blaettler, William Camu, Magdalena Kuzma-Kozakiewicz, Leonard H van den Berg, Raul Juntas Morales, Adriano Chio, Peter M Andersen, Pierre-Francois Pradat, Dale Lange, Philip Van Damme, Gabriele Mora, Mariusz Grudniak, Matthew Elliott, Susanne Petri, Nicholas Olney, Shafeeq Ladha, Shafeeq S. Ladha, Namita A Goyal, Thomas Meyer, Michael G Hanna, Colin Quinn, Angela Genge, Lorne Zinman, Duaa Jabari, Christen Shoesmith, Albert C Ludolph, Christoph Neuwirth, Sharon Nations, Jeremy M Shefner, Martin R Turner, Joanne Wuu, Richard Bennett, Hoang Dang, Claus Sundgreen
Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice
Date: 12/2023
Authors: Michael Benatar, Lyle W. Ostrow, Joseph W. Lewcock, Frank Bennett, Jeremy Shefner, Robert Bowser, Paul Larkin, Lucie Bruijn, Joanne Wuu
Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers: A Review
Date: 12/2022
Authors: Jeremy M. Shefner, Richard Bedlack, Jinsy A. Andrews, James D. Berry, Robert Bowser, Robert Brown, Jonathan D. Glass, Nicholas J. Maragakis, Timothy M. Miller, Jeffrey D. Rothstein, Merit E. Cudkowicz
Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development.
Date: 02/2022
Authors: Sabrina Paganoni, James D Berry, Melanie Quintana, Eric Macklin, Benjamin R Saville, Michelle A Detry, Marianne Chase, Alexander V Sherman, Hong Yu, Kristin Drake, Jinsy Andrews, Jeremy Shefner, Lori B Chibnik, Matteo Vestrucci, Merit E Cudkowicz, Shafeeq S. Ladha
Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design
Date: 09/2021
Authors: James Berry, Benjamin Brooks, Angela Genge, Terry Heiman-Patterson, Stanley Appel, Michael Benatar, Robert Bowser, R. Bowser, Merit Cudkowicz, Clifton Gooch, Jeremy Shefner, Jurjen Westra, Wendy Agnese, Charlotte Merrill, Sally Nelson, Stephen Apple
- English